Our innovative 222nm Plasma Guard lamp uses “microplasma” technology, a new radiation source capable of generating 222 nm wavelength in a slim and flat form. Our patented, flat-panel technologies have been shown to inactivate up to 90% of potentially harmful bacteria and viruses in the air and on surface areas. As importantly, the science shows that our lamps – operating in the 222nm spectrum – can be effective in that role while remaining safe for people occupying the space. As a leader in the market for commercialization of Far UV-C solutions, we are proud to say we are taking a responsible approach to understand and fully meeting all of our compliance obligations.

Studies have shown that a very small dose (2 mJ/cm2) of 222 nm was highly efficient in inactivating aerosolized H1N1 influenza virus. Recent scientific studies have demonstrated the efficacy of 222 nm light against two airborne human coronaviruses: alpha HCoV-229E and beta HCoV-OC43. Both were isolated over 50 years ago and are endemic to the human population, causing 15–30% of respiratory tract infections each year.

The results together with previous safety studies suggest the utility of continuous low-dose-rate 222 nm light in occupied indoor public locations such as hospitals, transportation vehicles, restaurants, airports and schools, potentially representing a safe and inexpensive tool to reduce the spread of airborne-mediated viruses. While staying within the current regulatory dose limits, low-dose-rate of our 222nm Plasma Guard exposure can potentially safely provide a major reduction in the ambient level of airborne coronaviruses including SARS-CoV-2.